H2S inhibition of chemical hypoxia-induced proliferation of HPASMCs is mediated by the upregulation of COX-2/PGI2

International Journal of Molecular Medicine

Volumn 33, Issue 2, 2014, Pages 359-366

  Li, Yunquan ^a   Liu, Guohui ^b   Cai, Dianqi ^b   Pan, Baoying ^b   Lin, Yuese ^a   Li, Xuandi ^a   Li, Shujuan ^a   Zhu, Ling ^a   Liao, Xinxue ^a   Wang, Huishen ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chemical hypoxia; Cyclooxygenase 2; Human pulmonary arterial smooth muscle cells; Hydrogen sulfide; Prostacyclin; Pulmonary arterial hypertension; Reactive oxygen species

Indexed keywords

COBALT CHLORIDE; CYCLOOXYGENASE 2; HYDROGEN SULFIDE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL HYPOXIA; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG ALVEOLUS CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; UPREGULATION;

ACETYLCYSTEINE; CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; COBALT; CYCLOOXYGENASE 2; DOWN-REGULATION; EPOPROSTENOL; HUMANS; HYDROGEN PEROXIDE; HYDROGEN SULFIDE; HYPERTENSION, PULMONARY; MYOCYTES, SMOOTH MUSCLE; OXIDATIVE STRESS; PULMONARY ARTERY; REACTIVE OXYGEN SPECIES; SULFIDES;

EID: 84893777185     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1579     Document Type: Article

References (42)

1. Schannwell CM, Steiner S and Strauer BE: Diagnostics in pulmonary hypertension. J Physiol Pharmacol 58 (Suppl 5): 591-602, 2007.
2. Fredenburgh LE, Liang OD, Macias AA, et al: Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation 117: 2114-2122, 2008.
3. Ismail S, Sturrock A, Wu P, et al: NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: The role of autocrine production of transforming growth factor-β1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol 296: L489-L499, 2009.
4. Burdon RH, Gill V and Rice-Evans C: Oxidative stress and tumour cell proliferation. Free Radic Res Commun 11: 65-76, 1990.
5. Immenschuh S and Baumgart-Vogt E: Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 7: 768-777, 2005.
6. Shimizu H, Hirose Y, Nishijima F, Tsubakihara Y and Miyazaki H: ROS and PDGF-β receptors are critically involved in indoxyl sulfate actions that promote vascular smooth muscle cell proliferation and migration. Am J Physiol Cell Physiol 297: C389-C396, 2009.
7. Tsukagoshi H, Busch W and Benfey PN: Transcriptional regulation of ROS controls transition from proliferation to differ-entiation in the root. Cell 143: 606-616, 2010.
8. Lakshminrusimha S, Russell JA, Wedgwood S, et al: Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am J Respir Crit Care Med 174: 1370-1377, 2006.
9. Zuckerbraun BS, Shiva S, Ifedigbo E, et al: Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation 121: 98-109, 2010.
10. Ruan CH, Dixon RA, Willerson JT and Ruan KH: Prostacyclin therapy for pulmonary arterial hypertension. Tex Heart Inst J 37: 391-399, 2010.
11. Pan TT, Feng ZN, Lee SW, Moore PK and Bian JS: Endogenous hydrogen sulfide contributes to the cardioprotection by metabolic inhibition preconditioning in the rat ventricular myocytes. J Mol Cell Cardiol 40: 119-130, 2006.
12. Wang XY, Yang CT, Zheng DD, et al: Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress. Mol Cell Biochem 363: 419-426, 2012.
13. Yang C, Yang Z, Zhang M, et al: Hydrogen sulfide protects against chemical hypoxia-induced cytotoxicity and inflamma-tion in HaCaT cells through inhibition of ROS/NF-kappaB/COX-2 pathway. PLoS One 6: E21971, 2011.
14. Wang R: Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. Physiol Rev 92: 791-896, 2012.
15. Hu LF, Pan TT, Neo KL, Yong QC and Bian JS: Cyclooxygenase-2 mediates the delayed cardioprotection induced by hydrogen sulfide preconditioning in isolated rat cardiomyocytes. Pflugers Arch 455: 971-978, 2008.
16. Jin Hongfang J, Cong Bailin, Zhao Bin, et al: Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. Life Sci 78: 1299-1309, 2006.
17. Wu C, Liu F, Zhou X, et al: Effect of protein kinase C on proliferation and apoptosis of T lymphocytes in idiopathic thrombocytopenic purpura children. Cell Mol Immunol 2: 197-203, 2005.
18. Yang C, Ling H, Zhang M, et al: Oxidative stress mediates chemical hypoxia-induced injury and inflammation by activating NF-kappab-COX-2 pathway in HaCaT cells. Mol Cells 31: 531-538, 2011.
19. Zhao Y, Bhushan S, Yang C, et al: Controllable hydrogen sulfide donors and the activity against myocardial ischemia-reperfusion injury. ACS Chem Biol 8: 1283-1290, 2013.
20. Liu C, Pan J, Li S, et al: Capture and visualization of hydrogen sulfide by a fluorescent probe. Angew Chem Int Ed Engl 50: 10327-10329, 2011.
21. Coruzzi G, Venturi N and Spaggiari S: Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: Selective COX-2 inhibitors and beyond. Acta Biomed 78: 96-110, 2007.
22. Badesch DB, Abman SH, Simonneau G, Rubin LJ and McLaughlin VV: Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 131: 1917-1928, 2007.
23. Simonneau G, Galie N, Rubin LJ, et al: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43: S5-S12, 2004.
24. Yu M, Gong D, Lim M, Arutyunyan A, Groffen J and Heisterkamp N: Lack of bcr and abr promotes hypoxia-induced pulmonary hypertension in mice. PLoS One 7: E49756, 2012.
25. Touyz RM: Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance? Hypertension 44: 248-252, 2004.
26. Landmesser U, Dikalov S, Price SR, et al: Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209, 2003.
27. Booth EA, Flint RR, Lucas KL, Knittel AK and Lucchesi BR: Estrogen protects the heart from ischemia-reperfusion injury via COX-2-derived PGI2. J Cardiovasc Pharmacol 52: 228-235, 2008.
28. Dore S, Otsuka T, Mito T, et al: Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 54: 155-162, 2003.
29. Kwak HJ, Park KM, Choi HE, Lim HJ, Park JH and Park HY: The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta. Cell Signal 22: 80-87, 2010.
30. Birnbaum Y, Ye Y, Rosanio S, et al: Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 65: 345-355, 2005.
31. Yang Z, Yang C, Xiao L, et al: Novel insights into the role of HSP90 in cytoprotection of H2S against chemical hypoxia-induced injury in H9c2 cardiac myocytes. Int J Mol Med 28: 397-403, 2011.
32. Zhao W, Zhang J, Lu Y and Wang R: The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J 20: 6008-6016, 2001.
33. Bhatia M: Hydrogen sulfide as a vasodilator. IUBMB Life 57: 603-606, 2005.
34. Cheng Y, Ndisang JF, Tang G, Cao K and Wang R: Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. Am J Physiol Heart Circ Physiol 287: H2316-H2323, 2004.
35. Shimizu K, Ogawa F, Hara T, et al: Exogenous application of hydrogen sulfide donor attenuates inflammatory reactions through the L-selectin-involved pathway in the cutaneous reverse passive Arthus reaction. J Leukoc Biol 93: 573-584, 2013.
36. Zhang C, Du J, Bu D, Yan H, Tang X and Tang C: The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats. Biochem Biophys Res Commun 302: 810-816, 2003.
37. Bearden SE, Beard RS Jr and Pfau JC: Extracellular transsulfuration generates hydrogen sulfide from homocysteine and protects endothelium from redox stress. Am J Physiol Heart Circ Physiol 299: H1568-H1576, 2010.
38. Yang G, Sun X and Wang R: Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3. FASEB J 18: 1782-1784, 2004.
39. Du J, Hui Y, Cheung Y, et al: The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart Vessels 19: 75-80, 2004.
40. Baskar R, Sparatore A, Del Soldato P and Moore PK: Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. Eur J Pharmacol 594: 1-8, 2008.
41. Wu B, Teng H, Yang G, Wu L and Wang R: Hydrogen sulfide inhibits the translational expression of hypoxia-inducible factor-1alpha. Br J Pharmacol 167: 1492-1505, 2012.
42. Kai S, Tanaka T, Daijo H, et al: Hydrogen sulfide inhibits hypoxia-but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau-and mitochondria-dependent manner. Antioxid Redox Signal 16: 203-216, 2012.